Aurélie Mbeutcha1,2, Morgan Rouprêt3, Ashish M Kamat4, Pierre I Karakiewicz5, Nathan Lawrentschuk6, Giacomo Novara7, Jay D Raman8, Christian Seitz1, Evanguelos Xylinas9, Shahrokh F Shariat10,11,12. 1. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria. 2. Department of Urology, University of Nice Sophia-Antipolis, Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, Nice, France. 3. Department of Urology, Pitié-Salpétrière Hospital, APHP, University Paris VI, Paris, France. 4. Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Urology, University of Montreal Health Center, Montreal, QC, Canada. 6. Department of Surgical Oncology, Peter MacCallum Cancer Centre and Department of Surgery/Olivia Newton John Cancer Centre, University of Melbourne, Melbourne, VIC, Australia. 7. Department of Surgery, Oncology, and Gastroenterology - Urology Clinic, University of Padua, Padua, Italy. 8. Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA. 9. Department of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, France. 10. Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austria. sfshariat@gmail.com. 11. Department of Urology, Weill Cornell Medical College, New York, NY, USA. sfshariat@gmail.com. 12. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. sfshariat@gmail.com.
Abstract
BACKGROUND: Upper tract urothelial carcinoma (UTUC) is a rare and heterogeneous disease. Several clinical and biological prognostic factors have been identified in multi-institutional collaborative works with the aim of helping decision-making in pursuit of tailored individual patient care. This review provides an overview of these existing prognostic factors and predictive tools for the management of patients with UTUC. METHODS: A systematic literature search was performed using PubMed/MEDLINE, Web of Science and Scopus databases regarding articles published in English between January 2000 and November 2015 according to PRISMA guidelines. Thresholds of 100 and 300 patients were applied for studies on biomarkers and clinical studies, respectively. All the studies on predictive tools were included for analysis. Outcomes of interest were features associated with advanced-stage UTUC, disease recurrence and survival. RESULTS: A total of 116 studies were included in this review. These large and/or multi-institutional studies have confirmed the prognostic value of standard pathological factors (i.e., tumor stage, grade and lymph node metastasis) and identified novel features such as lymphovascular invasion, tumor architecture, multifocality, concomitant CIS, variant histology and biomarker status among others. Based on these variables, several predictive tools have been developed; however, they often lack of validation. The value of these features and tools needs prospective testing. CONCLUSION: Efforts provided by international collaboration groups have permitted to validate established features and identify new features of biologically and clinically aggressive UTUC. Further investigation on prognostic factors and biomarkers is still needed to assess the benefit of these features and tools on clinical decision-making.
BACKGROUND:Upper tract urothelial carcinoma (UTUC) is a rare and heterogeneous disease. Several clinical and biological prognostic factors have been identified in multi-institutional collaborative works with the aim of helping decision-making in pursuit of tailored individual patient care. This review provides an overview of these existing prognostic factors and predictive tools for the management of patients with UTUC. METHODS: A systematic literature search was performed using PubMed/MEDLINE, Web of Science and Scopus databases regarding articles published in English between January 2000 and November 2015 according to PRISMA guidelines. Thresholds of 100 and 300 patients were applied for studies on biomarkers and clinical studies, respectively. All the studies on predictive tools were included for analysis. Outcomes of interest were features associated with advanced-stage UTUC, disease recurrence and survival. RESULTS: A total of 116 studies were included in this review. These large and/or multi-institutional studies have confirmed the prognostic value of standard pathological factors (i.e., tumor stage, grade and lymph node metastasis) and identified novel features such as lymphovascular invasion, tumor architecture, multifocality, concomitant CIS, variant histology and biomarker status among others. Based on these variables, several predictive tools have been developed; however, they often lack of validation. The value of these features and tools needs prospective testing. CONCLUSION: Efforts provided by international collaboration groups have permitted to validate established features and identify new features of biologically and clinically aggressive UTUC. Further investigation on prognostic factors and biomarkers is still needed to assess the benefit of these features and tools on clinical decision-making.
Authors: Ricardo L Favaretto; Shahrokh F Shariat; Caroline Savage; Guilherme Godoy; Daher C Chade; Matthew Kaag; Bernard H Bochner; Jonathan Coleman; Guido Dalbagni Journal: BJU Int Date: 2011-06-01 Impact factor: 5.588
Authors: Kazumasa Matsumoto; Giacomo Novara; Amit Gupta; Vitaly Margulis; Thomas J Walton; Marco Roscigno; Casey Ng; Eiji Kikuchi; Richard Zigeuner; Wassim Kassouf; Hans-Martin Fritsche; Vincenzo Ficarra; Guido Martignoni; Stefan Tritschler; Joaquin Carballido Rodriguez; Christian Seitz; Alon Weizer; Mesut Remzi; Jay D Raman; Christian Bolenz; Karim Bensalah; Theresa M Koppie; Pierre I Karakiewicz; Christopher G Wood; Francesco Montorsi; Masatsugu Iwamura; Shahrokh F Shariat Journal: BJU Int Date: 2011-04-20 Impact factor: 5.588
Authors: Wolfgang Otto; Shahrokh F Shariat; Hans-Martin Fritsche; Amit Gupta; Kazumasa Matsumoto; Wassim Kassouf; Guido Martignoni; Thomas J Walton; Stefan Tritschler; Shiro Baba; Patrick J Bastian; Juan I Martínez-Salamanca; Christian Seitz; Armin Pycha; Maximilian Burger; Pierre I Karakiewicz; Vincenzo Ficarra; Giacomo Novara Journal: World J Urol Date: 2011-01-20 Impact factor: 4.226
Authors: Pierre Colin; Adil Ouzzane; David R Yates; François Audenet; Audenet François; Géraldine Pignot; Alexis Arvin-Berod; Olivier Merigot de Treigny; Guy Laurent; Antoine Valeri; Jacques Irani; Irani Jacques; Fabien Saint; Solène Gardic; Pascal Gres; François Rozet; Yann Neuzillet; Alain Ruffion; Morgan Rouprêt Journal: Ann Surg Oncol Date: 2012-07-28 Impact factor: 5.344
Authors: Johanna M M van Oers; Ellen C Zwarthoff; Ishtiaq Rehman; Abdel-Rahmene Azzouzi; Olivier Cussenot; Mark Meuth; Freddie C Hamdy; James W F Catto Journal: Eur Urol Date: 2008-06-13 Impact factor: 20.096
Authors: Shahrokh F Shariat; Guilherme Godoy; Yair Lotan; Michael Droller; Pierre I Karakiewicz; Jay D Raman; Hendrik Isbarn; Alon Weizer; Mesut Remzi; Marco Roscigno; Eiji Kikuchi; Christian Bolenz; Karim Bensalah; Theresa M Koppie; Wassim Kassouf; Jeffrey C Wheat; Richard Zigeuner; Cord Langner; Christopher G Wood; Vitaly Margulis Journal: BJU Int Date: 2009-11-13 Impact factor: 5.588
Authors: D R Yates; V Hupertan; P Colin; A Ouzzane; A Descazeaud; J A Long; G Pignot; S Crouzet; F Rozet; Y Neuzillet; M Soulie; T Bodin; A Valeri; O Cussenot; M Rouprêt Journal: Br J Cancer Date: 2012-02-28 Impact factor: 7.640
Authors: Bjarte Almås; Stein Øverby; Ole J Halvorsen; Lars A R Reisæter; Jørg Assmus; Birgitte Carlsen; Anders Loe; Christian Beisland Journal: World J Urol Date: 2019-05-23 Impact factor: 4.226
Authors: Eu Chang Hwang; Niranjan J Sathianathen; Jae Hung Jung; Myung Ha Kim; Philipp Dahm; Michael C Risk Journal: Cochrane Database Syst Rev Date: 2019-05-18
Authors: Aurélie Mbeutcha; Romain Mathieu; Morgan Rouprêt; Kilian M Gust; Alberto Briganti; Pierre I Karakiewicz; Shahrokh F Shariat Journal: Transl Androl Urol Date: 2016-10
Authors: Ho Song Yu; Jun Eul Hwang; Ho Seok Chung; Yang Hyun Cho; Myung Soo Kim; Eu Chang Hwang; Kyung Jin Oh; Sun-Ouck Kim; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park; Soo Bang Ryu; Sung-Hoon Jung; Young Hoe Hur; Joon Hwa Noh; Myung Ki Kim; Ill Young Seo; Chul-Sung Kim; Sung Gu Kang; Seok Ho Kang; Jun Cheon Journal: Oncotarget Date: 2017-03-15
Authors: Laura Izquierdo; Ruth Montalbo; Mercedes Ingelmo-Torres; Carme Mallofré; Miguel Ramírez-Backhaus; Jose Rubio; Antoine G Van der Heijden; Ewout Schaafsma; Antonio Lopez-Beltran; Ana Blanca; Nathan Lawrentschuk; Antonio Alcaraz; Lourdes Mengual Journal: Oncotarget Date: 2017-05-16